-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Caris Life Sciences, Lowers Price Target to $30

Benzinga·04/06/2026 16:59:17
Listen to the news
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and lowers the price target from $34 to $30.